Novel biomarkers for improving diagnostics, prognostics, and treatments of Alzheimer’s disease
ADVANCE-AD aims to enhance Alzheimer's diagnostics and treatment by developing cost-effective blood-based biomarkers and algorithms for early detection and intervention in pre-symptomatic patients.
Projectdetails
Introduction
Alzheimer’s disease (AD) is the most common cause of dementia and a major global health challenge. AD has a long pre-symptomatic phase spanning several decades. The accuracy of clinical AD diagnostics is mediocre, especially in primary care. This results in suboptimal treatment and care, which is especially problematic in light of emerging anti-amyloid therapies.
Project Goals
ADVANCE-AD aims to revolutionize AD diagnostics and prognostics and fast-track the development of new effective therapies by using novel blood-based biomarkers for beta-amyloid, tau, neurodegeneration, and neuroinflammation.
Transforming Clinical Work-Up
First, my team will transform the clinical work-up of symptomatic AD patients globally by developing scalable, non-invasive, and cost-effective diagnostic and prognostic algorithms based on novel blood-based biomarkers and digital tools.
Early Intervention
Second, disease-modifying therapies should be initiated already in the pre-symptomatic phase to be very effective. My team will therefore develop cost-effective diagnostic algorithms to:
- Identify AD pathology in individuals without cognitive symptoms.
- Detect those most likely to develop symptoms and thereby benefit from new therapies.
These new algorithms will then be used to recruit individuals into a pre-symptomatic trial-ready cohort to efficiently evaluate new anti-AD drugs.
Identifying Drug Candidates
Third, new drug candidates for our trial-ready cohort will be identified using large-scale analyses of the novel AD-related biomarkers in biobanked longitudinal blood samples from already performed randomized placebo-controlled trials.
Using this high risk/high-gain approach, we will evaluate if different classes of existing drugs (e.g., statins, GLP-1 agonists, anti-inflammatory agents) can halt the development of AD and neurodegeneration.
Evaluating Novel Treatments
Finally, a novel genetic anti-tau treatment will be evaluated in this trial-ready cohort.
Conclusion
ADVANCE-AD builds on world-leading research and will likely result in breakthroughs in early diagnostics and treatments for AD.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 2.500.000 |
Totale projectbegroting | € 2.500.000 |
Tijdlijn
Startdatum | 1-1-2024 |
Einddatum | 31-12-2028 |
Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- LUNDS UNIVERSITETpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Fluid Biomarkers for Neurodegenerative DementiasThe project aims to develop high-throughput biomarker tools for Alzheimer's and neurodegenerative diseases, enabling comprehensive analysis for diagnostics, drug discovery, and personalized medicine. | ERC Advanced... | € 2.422.973 | 2022 | Details |
Deciphering Alzheimer’s disease molecular subtypes to advance treatment development.This project aims to identify Alzheimer's disease subtypes through CSF proteomics to develop tailored treatments and theragnostic tools linked to cognitive decline and genetic factors. | ERC Consolid... | € 2.999.934 | 2025 | Details |
Targetting neutrophil-mediated neurotoxicity for the treatment of Alzheimer's DiseaseThe NeutrAD project aims to develop and commercialize the first disease-modifying Alzheimer's drugs targeting neutrophil-mediated neurotoxicity, with promising results in preclinical models. | ERC Proof of... | € 150.000 | 2022 | Details |
Repurposing a human drug to treat Alzheimer’s diseaseThis project aims to validate an approved drug that inhibits tau accumulation in Alzheimer's, advancing it towards commercialization as a novel treatment for the disease. | ERC Proof of... | € 150.000 | 2022 | Details |
Gamma-secretase allosteric modulation as preventive therapy in Alzheimer’s DiseaseThis project aims to validate gamma-secretase allosteric modulators as safe, effective, and affordable preventative treatments for Alzheimer's Disease using an innovative xenotransplantation model. | ERC Proof of... | € 150.000 | 2024 | Details |
Fluid Biomarkers for Neurodegenerative Dementias
The project aims to develop high-throughput biomarker tools for Alzheimer's and neurodegenerative diseases, enabling comprehensive analysis for diagnostics, drug discovery, and personalized medicine.
Deciphering Alzheimer’s disease molecular subtypes to advance treatment development.
This project aims to identify Alzheimer's disease subtypes through CSF proteomics to develop tailored treatments and theragnostic tools linked to cognitive decline and genetic factors.
Targetting neutrophil-mediated neurotoxicity for the treatment of Alzheimer's Disease
The NeutrAD project aims to develop and commercialize the first disease-modifying Alzheimer's drugs targeting neutrophil-mediated neurotoxicity, with promising results in preclinical models.
Repurposing a human drug to treat Alzheimer’s disease
This project aims to validate an approved drug that inhibits tau accumulation in Alzheimer's, advancing it towards commercialization as a novel treatment for the disease.
Gamma-secretase allosteric modulation as preventive therapy in Alzheimer’s Disease
This project aims to validate gamma-secretase allosteric modulators as safe, effective, and affordable preventative treatments for Alzheimer's Disease using an innovative xenotransplantation model.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Dementia/Alzheimer Drug Attributed to Cystatin-C and other mutations – precision medicine drug developmentATI's AT-001 aims to stop and revert dementia by preventing protein aggregation, with promising Phase IIa results leading to upcoming registration trials and POC studies for commercialization. | EIC Accelerator | € 2.500.000 | 2023 | Details |
Human Antibody-enabled Cardiovascular Personalized TheranosisABCardionostics aims to develop a multi-marker PET/MRI system using human antibodies to personalize treatment and improve diagnosis of atherosclerosis in vulnerable patients. | EIC Pathfinder | € 3.639.665 | 2024 | Details |
Lontaine Disease Prediction PlatformLontaine ontwikkelt een innovatief algoritme op basis van neurale netwerken om de ziekte van Alzheimer en Parkinson vroegtijdig en individueel te voorspellen, met als doel de zorgkosten te verlagen en de levenskwaliteit te verbeteren. | Mkb-innovati... | € 20.000 | 2021 | Details |
Towards the clinical implementation of TREM2 Microglia Engineering for treating DementiaSTREM2MEDS aims to transition a novel gene therapy for Alzheimer’s and Nasu-Hakola Diseases from preclinical validation to a Phase I clinical trial, targeting TREM2 dysfunction in microglia. | EIC Transition | € 2.499.721 | 2024 | Details |
Dementia/Alzheimer Drug Attributed to Cystatin-C and other mutations – precision medicine drug development
ATI's AT-001 aims to stop and revert dementia by preventing protein aggregation, with promising Phase IIa results leading to upcoming registration trials and POC studies for commercialization.
Human Antibody-enabled Cardiovascular Personalized Theranosis
ABCardionostics aims to develop a multi-marker PET/MRI system using human antibodies to personalize treatment and improve diagnosis of atherosclerosis in vulnerable patients.
Lontaine Disease Prediction Platform
Lontaine ontwikkelt een innovatief algoritme op basis van neurale netwerken om de ziekte van Alzheimer en Parkinson vroegtijdig en individueel te voorspellen, met als doel de zorgkosten te verlagen en de levenskwaliteit te verbeteren.
Towards the clinical implementation of TREM2 Microglia Engineering for treating DementiaS
TREM2MEDS aims to transition a novel gene therapy for Alzheimer’s and Nasu-Hakola Diseases from preclinical validation to a Phase I clinical trial, targeting TREM2 dysfunction in microglia.